Lenalidomide in Patients With Chronic Myelomonocytic Leukemia

Status Active, not recruiting

Clinical Trial Summary

In a phase I study the investigators plan to investigate safety and toxicity of lenalidomide in patients with Chronic Myelomonocytic Leukemia (CMML). A phase II study will be started once an optimal dose has been found. The primary endpoint will concern the efficacy of lenalidomide in patients with CMML according to the WHO diagnostic criteria.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01368757
Study type	Interventional
Source	Arbeitsgemeinschaft medikamentoese Tumortherapie
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	June 2010
Completion date	May 2015

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04093570` - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers	Phase 2
Active, not recruiting	`NCT03289910` - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia	Phase 2
Recruiting	`NCT06159491` - Pacritinib in CMML	Phase 1/Phase 2
Completed	`NCT01427881` - Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Phase 2
Recruiting	`NCT01133886` - Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure	Phase 2
Completed	`NCT01169012` - PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias	Phase 1
Completed	`NCT01233921` - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	N/A
Completed	`NCT01093586` - Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Phase 2
Terminated	`NCT00509249` - Aflibercept in Treating Patients With Myelodysplastic Syndromes	Phase 2
Terminated	`NCT00387426` - Sunitinib in Treating Patients With Idiopathic Myelofibrosis	Phase 2
Completed	`NCT00096122` - Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia	Phase 1/Phase 2
Completed	`NCT00171912` - Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes	Phase 2
Completed	`NCT00078858` - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Phase 1/Phase 2
Completed	`NCT00052520` - Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation	Phase 1/Phase 2
Recruiting	`NCT03683433` - Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation	Phase 2
Recruiting	`NCT04980404` - Inqovi Maintenance Therapy in Myeloid Neoplasms	Phase 1
Active, not recruiting	`NCT03588078` - Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine	Phase 1/Phase 2
Withdrawn	`NCT06085638` - Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia	Phase 1/Phase 2
Recruiting	`NCT03999723` - Combining Active and Passive DNA Hypomethylation	Phase 2
Terminated	`NCT00852709` - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias	Phase 1